These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 21257648

  • 1. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
    Herbild L, Bech M, Gyrd-Hansen D, Christensen M, Werge T, Nielsen KA.
    Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
    [Abstract] [Full Text] [Related]

  • 2. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings.
    Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, Fava M, Perlis R, Brennan FX, Lombard J.
    Am J Manag Care; 2014 May; 20(5):e146-56. PubMed ID: 25326929
    [Abstract] [Full Text] [Related]

  • 3. Is pharmacogenetic CYP2D6 testing useful?
    Vetti HH, Molven A, Eliassen AK, Steen VM.
    Tidsskr Nor Laegeforen; 2010 Nov 18; 130(22):2224-8. PubMed ID: 21109842
    [Abstract] [Full Text] [Related]

  • 4. Nurses' genetic/genomics competencies when medication therapy is guided by pharmacogenetic testing: children with mental health disorders as an exemplar.
    Prows CA, Saldaña SN.
    J Pediatr Nurs; 2009 Jun 18; 24(3):179-88. PubMed ID: 19467430
    [Abstract] [Full Text] [Related]

  • 5. Current applications of clinical genetic testing for psychiatric practice.
    Mrazek DA.
    Minn Med; 2007 Jan 18; 90(1):42-3. PubMed ID: 17305105
    [Abstract] [Full Text] [Related]

  • 6. Costs associated with attempted suicide among individuals with bipolar disorder.
    Stensland MD, Zhu B, Ascher-Svanum H, Ball DE.
    J Ment Health Policy Econ; 2010 Jun 18; 13(2):87-92. PubMed ID: 20919595
    [Abstract] [Full Text] [Related]

  • 7. [Therapeutic monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry].
    Voirol P, Eap CB, Baumann P.
    Rev Med Suisse Romande; 2000 Feb 18; 120(2):99-104. PubMed ID: 10748694
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacogenetic considerations in the treatment of psychiatric disorders.
    Lohoff FW, Ferraro TN.
    Expert Opin Pharmacother; 2010 Feb 18; 11(3):423-39. PubMed ID: 20102306
    [Abstract] [Full Text] [Related]

  • 9. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
    Preskorn SH.
    J Psychiatr Pract; 2010 May 18; 16(3):177-82. PubMed ID: 20485106
    [Abstract] [Full Text] [Related]

  • 10. Regional variations and determinants of direct psychiatric costs in Sweden.
    Tiainen A, Edman G, Flyckt L, Tomson G, Rehnberg C.
    Scand J Public Health; 2008 Jul 18; 36(5):483-92. PubMed ID: 18635731
    [Abstract] [Full Text] [Related]

  • 11. The Impact of Psychiatric Practice Guidelines on Medication Costs and Youth Aggression in a Juvenile Justice Residential Treatment Program.
    Lee TG, Walker SC, Bishop AS.
    Psychiatr Serv; 2016 Feb 18; 67(2):214-20. PubMed ID: 26423102
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacogenetics/pharmacogenomics in psychiatry].
    Ueda M, Ishiguro S, Watanabe T, Saeki Y, Shimoda K.
    Nihon Rinsho; 2010 Jan 18; 68(1):155-62. PubMed ID: 20077810
    [Abstract] [Full Text] [Related]

  • 13. Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting.
    Brown LC, Lorenz RA, Li J, Dechairo BM.
    Clin Ther; 2017 Mar 18; 39(3):592-602.e1. PubMed ID: 28238356
    [Abstract] [Full Text] [Related]

  • 14. [Clinical significance of pharmacogenetics in psychiatry].
    Skrętkowicz J, Barańska M, Rychlik-Sych M.
    Wiad Lek; 2013 Mar 18; 66(2 Pt 2):185-91. PubMed ID: 25775815
    [Abstract] [Full Text] [Related]

  • 15. Where are we today with personalized medicine?
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2012 Nov 18; 50(11):11-3. PubMed ID: 23066831
    [Abstract] [Full Text] [Related]

  • 16. Personalized pharmacotherapy in psychiatry.
    Filaković P, Petek A.
    Psychiatr Danub; 2009 Sep 18; 21(3):341-6. PubMed ID: 19794353
    [Abstract] [Full Text] [Related]

  • 17. Examination of the effects of financial risk on the formal treatment costs for a Medicaid population with psychiatric disabilities.
    Jones K, Chen HJ, Jordan N, Boothroyd RA, Ramoni-Perazzi J, Shern DL.
    Med Care; 2006 Apr 18; 44(4):320-7. PubMed ID: 16565632
    [Abstract] [Full Text] [Related]

  • 18. Trends in mental health cost growth: an expanded role for management?
    Frank RG, Goldman HH, McGuire TG.
    Health Aff (Millwood); 2009 Apr 18; 28(3):649-59. PubMed ID: 19414870
    [Abstract] [Full Text] [Related]

  • 19. Reconceptualizing medication adherence: six phases of dynamic adherence.
    Gearing RE, Townsend L, MacKenzie M, Charach A.
    Harv Rev Psychiatry; 2011 Apr 18; 19(4):177-89. PubMed ID: 21790266
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.